No difference in BCMA levels, before or after γ-secretase inhibitor treatment, was observed between CLL samples with mutated and unmutated immunoglobulin heavy chain variable region gene status (Fig. 2D and E). This evidence concerns the gene TNFRSF17 and B-cell chronic lymphocytic leukemia.